Zafirlukast is commonly recognized as a leukotriene receptor antagonist which is used in the treatment of asthma. It is found to be a potent inhibitor of VEGF-C/Nrp2. Research on topical usage suggests that zafirlukast may also be effective in preventing capsular contracture and reducing capsule formation of gel implants, a complication arising after breast implant surgery.
| Cas No. | 107753-78-6 |
|---|---|
| Purity | ≥98% |
| Formula | C31H33N3O6S |
| Formula Wt. | 575.68 |
| IUPAC Name | Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate |
| Melting Point | 138-140°C |
| Solubility | Soluble in DMSO (25 mg/ml). |
| Appearance | White to pink powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | Z0222 Info Sheet PDF |
|---|
Oda S, Fijiwara R, Kutsuno Y, et al. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Drug Metal Dispos. 2015 Jun; 43(6):812-818. PMID: 25834030.
Bandaru S, Marri VK, Kasera P, et al. Structure based virtual screening of ligands to identify cysteinyl leukotriene receptor 1 antagonist. Bioinformation. 2014 Oct 30; 10(10):652-657. PMID: 25489175.
Kang SH, Shin KC, Kim WS, et al. The preventive effect of topical zafirlukast instillation for peri-implant capsule formation in rabbits. Arch Plast Surg. 2015 Mar; 42(2):179-185. PMID: 25798389.
